One‐Year Outcomes of High‐Risk Percutaneous Coronary Interventions With Versus Without Mechanical Circulatory Support: Propensity Score‐Matched Analysis
- 28 July 2026
- journal article
- Published by Wiley in Catheterization and Cardiovascular Interventions
Abstract
Background: Impella is increasingly used as mechanical circulatory support (MCS) during high‐risk percutaneous coronary interventions (HR‐PCI). Registry‐based data provide insights into the efficacy and safety of Impella‐assisted HR‐PCI. Aims: We aimed to evaluate 1‐year outcomes of Impella‐assisted HR‐PCI compared to HR‐PCI without MCS. Methods: One hundred and thirty‐eight patients undergoing Impella‐assisted PCI, included in the IMPELLA‐PL registry, were propensity score‐matched with controls from the retrospective CardioSilesia registry who underwent HR‐PCI without MCS. Study endpoints included 1‐year post‐discharge all‐cause mortality, myocardial infarction (MI), stroke, rehospitalization for heart failure (HF), and repeat coronary revascularization. Results: Clinical and angiographic characteristics were comparable in both groups, with higher rates of dyslipidemia (78.3% vs. 37.7%, p < 0.001), chronic kidney disease (39.9% vs. 16.7%, p < 0.001), and peripheral artery disease (34.1% vs. 8.0%, p < 0.001) in the IMPELLA‐PL cohort. Intravascular ultrasound was more frequently used in the Impella‐supported patients (44.2% vs. 25.4%, p = 0.002), while staged revascularization was more common among controls (30.4% vs. 15.9%, p = 0.007). At 1 year, rates of post‐discharge all‐cause mortality, stroke, and repeat coronary revascularization were similar in both groups. MI was less frequent in the IMPELLA‐PL cohort (1.4% vs. 10.9%, p = 0.003), alongside a trend toward lower incidence of rehospitalizations for HF (9.4% vs. 18.1%, p = 0.055). Conclusions: Despite an unfavorable cardiovascular risk profile, patients who underwent Impella‐assisted HR‐PCI had similar 1‐year post‐discharge survival, with a lower rate of MI, compared to propensity score‐matched controls who underwent HR‐PCI without MCS. Impella may improve HR‐PCI outcomes in selected patients, but further randomized controlled trials are required to confirm this finding.Keywords
This publication has 25 references indexed in Scilit:
- Procedural characteristics and outcomes of patients undergoing Impella-assisted high-risk percutaneous coronary interventions in the IMPELLA-PL registryCardiovascular Revascularization Medicine, 2025
- Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset AnalysisThe American Journal of Cardiology, 2022
- Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practicesAmerican Heart Journal, 2022
- High-Risk Percutaneous Coronary Intervention of Native Coronary Arteries Without Mechanical Circulatory Support in Acute Coronary Syndrome Without Cardiogenic ShockThe American Journal of Cardiology, 2021
- Outcomes of Impella‐supported high‐risk nonemergent percutaneous coronary intervention in a large single‐center registryCatheterization and Cardiovascular Interventions, 2020
- Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCIInternational Journal of Cardiology, 2019
- Impella support and acute kidney injury during high‐risk percutaneous coronary intervention: The Global cVAD Renal Protection StudyCatheterization and Cardiovascular Interventions, 2019
- The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failureAmerican Heart Journal, 2018
- Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registryClinical Research in Cardiology, 2018
- Impact of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial)The American Journal of Cardiology, 2014